Golimumab in Juvenile Idiopathic Arthritis-associated Uveitis Failing Adalimumab

Sponsor
Medical University of Graz
Study ID
NCT04200833
Status
Completed

Conditions

  • JIA Associated Uveitis

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To asses the use of golimumab, a fully humanized anti-TNF Alpha monoclonal antibody, in juvenile idiopathic Arthritis-associated uveitis refractory to adalimumab.

Key Dates

Start date
Mar 1, 2010
Status verified
Apr 2022
Primary completion
Jul 1, 2021
Completion
Aug 1, 2021

Study Design

Enrollment
10 participants (actual)

Arms

  • Arm: group 1
    All JIA patients that were switched from adalimumab to golimumab because of Treatment failure of their JIA associated uveitis at the Medical University of Graz Austria from 2010 to 2019

Primary Outcome Measure

Number of Participants Reported as Complete Responders to Golimumab [ Time Frame: last follow up, up to 5 years ]